ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
COVID toes: where do we stand with the current evidence?
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.International journal of dermatology · 2022Pooled it
- Are the chilblain-like lesions observed during the COVID-19 pandemic due to severe acute respiratory syndrome coronavirus 2? Systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- [Guideline S1: Long COVID: Diagnostics and treatment strategies].Wiener klinische Wochenschrift · 2021Guideline
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Article
- Postacute Sequelae of SARS-CoV-2 in Children.Pediatrics · 2024Review
- Unmasking the Enigma of the COVID Toe.Cureus · 2023Article
- [S1 guidelines for the management of postviral conditions using the example of post-COVID-19].Wiener klinische Wochenschrift · 2023Article
- [The problem of long/post-COVID in expert assessments].Unfallchirurgie (Heidelberg, Germany) · 2023Review
- Violaceous Papules and Plaques on the Fingers during COVID-19: A Quiz.Acta dermato-venereologica · 2023Article
- "COVID toes": A true viral phenomenon or a diagnosis without a leg to stand on?JAAD international · 2022Review
- SARS-CoV-2 Vaccination and Chilblain-like Lesions: What Do We Know so Far?Dermatology practical & conceptual · 2022Review
- Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19.JCI insight · 2022Article
- COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?International journal of molecular sciences · 2022Review
- Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19.medRxiv : the preprint server for health sciences · 2022Article
- Experience with Cutaneous Manifestations in COVID-19 Patients during the Pandemic.Journal of clinical medicine · 2022Article
- "COVID Toes" in Three Siblings.The Pediatric infectious disease journal · 2021Article
- From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic‒Associated Pernio.The Journal of investigative dermatology · 2021Review
- Top 10 acral skin manifestations associated with COVID-19: A scoping review.Dermatologic therapy · 2021Article
- Clinical Patterns and Morphology of COVID-19 Dermatology.Dermatologic clinics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous of cases of chilblains have been observed, mainly in young subjects with no or mild symptoms compatible with COVID-19. The pathophysiology of these lesions is still widely debated and an association with SARS-CoV-2 infection remains unconfirmed.
objectivesThis paper focus on the unresolved issues about these COVID toes and in particular whether or not they are associated with COVID-19. ARGUMENTS: The temporal link between the outbreak of chilblains and the COVID-19 pandemic is a first suggests a link between the two events. Positive anti-SARS-CoV/SARS-CoV-2 immunostaining on skin biopsy of chilblains seem to confirm the presence of the virus in the lesions, but lack specificity and must be interpreted with caution. Conversely, RT-PCR and anti-SARS-CoV-2 serology were negative in the majority of patients with chilblains. Therefore, SARS-CoV-2 infection can be excluded, with relative certainty, even after accounting for possible lower immunization in mild/asymptomatic patients and for some differences in sensitivity/specificity between the tests used. Some authors hypothesize that chilblains could be the cutaneous expression of a strong type I interferon (IFN-I) response. High production of IFN-I is suggested to be associated with early viral control and may suppress antibody response. However, the absence of other cutaneous or extracutaneous symptoms as observed in other interferonopathies raises unanswered questions. To date, a direct link between chilblains and COVID-19 still seems impossible to confirm. A more indirect association due to lifestyle changes induced by lockdown is a possible explanation. Improvement of chilblains when protective measures were adopted and after lifting of lockdown, support this hypothesis.
conclusionConflicting current evidence highlights the need for systematic and repeated testing of larger numbers of patients and the need for valid follow-up data that take into consideration epidemic curves and evolution of lockdown measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.